Van Vugt D A, Heisler L E, Reid R L
Department of Obstetrics and Gynecology, Queen's University, Kingston, Ontario, Canada.
J Clin Endocrinol Metab. 1992 Jun;74(6):1312-9. doi: 10.1210/jcem.74.6.1592876.
Administration of an estrogen challenge during the luteal phase, a time when progesterone concentrations are elevated, fails to elicit a gonadotropin-positive feedback response. The purpose of the present study was to determine if endogenous opiates are involved in the mechanism by which progesterone blocks the estrogen-induced gonadotropin surge in monkeys. To this end, rhesus monkeys in the luteal phase were pretreated with either saline or various regimens of nalmefene, a long-acting opiate antagonist, before being given an estrogen challenge. Three groups of animals were given nalmefene (10 mg, iv) every 12 h beginning 24, 48, or 96 h before an estrogen challenge and continued until 48 h after the start of the estrogen challenge. A fourth group received a continuous sc infusion of nalmefene (20 mg/day) via osmotic minipumps beginning 48 h in advance of the estrogen challenge. In a second experiment, monkeys in the follicular phase received progesterone implants at the time of an estrogen challenge and iv injections of nalmefene every 12 h for 48 h. Gonadotropin and steroid levels were monitored in both experiments by collecting blood samples by saphenous venipuncture at intervals of 6-12 h. The majority of luteal phase animals that were pretreated with saline were unresponsive to the estrogen challenge. Only 2 of 16 (12.5%) had an increase in LH concentrations that could be classified as a surge. Animals pretreated with iv nalmefene every 12 h beginning 48 h before the estrogen challenge exhibited a higher incidence of positive feedback responses (8 of 12 or 66.7%). A concomitant FSH surge was observed in 3 of these instances. However, when progesterone concentrations, which declined before the estrogen challenge in the nalmefene-treated group, were supplemented with exogenous progesterone, nalmefene failed to evoke any LH surges. Six of 8 animals that received nalmefene by sc infusion exhibited LH responses. However, the amplitude and duration of these LH responses were diminished, and no FSH responses were observed. Monkeys pretreated with nalmefene for either shorter (24 h) or longer (96 h) periods before the challenge were less responsive (0 responses out of 6 trials and 1 response out of 4 trials, respectively). Nalmefene was equally ineffective in preventing progesterone inhibition of the estradiol-induced LH surge in follicular phase animals (0 of 15 animals had LH surge). These results indicate that nalmefene antagonism of endogenous opiates does not enable estrogen to exert positive feedback effects on LH release when progesterone levels are high, such as during the luteal phase or after progesterone administration.(ABSTRACT TRUNCATED AT 400 WORDS)
在黄体期给予雌激素激发试验,此时孕酮浓度升高,未能引发促性腺激素阳性反馈反应。本研究的目的是确定内源性阿片类物质是否参与孕酮阻断雌激素诱导的猴子促性腺激素激增的机制。为此,在给予雌激素激发试验之前,对处于黄体期的恒河猴用生理盐水或不同方案的纳美芬(一种长效阿片拮抗剂)进行预处理。三组动物在雌激素激发试验前24、48或96小时开始,每12小时静脉注射一次纳美芬(10毫克),并持续至雌激素激发试验开始后48小时。第四组在雌激素激发试验前48小时开始通过渗透微型泵持续皮下输注纳美芬(20毫克/天)。在第二个实验中,处于卵泡期的猴子在雌激素激发试验时植入孕酮,并每12小时静脉注射一次纳美芬,持续48小时。在两个实验中,通过隐静脉穿刺每隔6 - 12小时采集血样来监测促性腺激素和类固醇水平。大多数用生理盐水预处理的黄体期动物对雌激素激发试验无反应。16只动物中只有2只(12.5%)促黄体生成素(LH)浓度升高可被归类为激增。在雌激素激发试验前48小时开始每12小时静脉注射纳美芬预处理的动物表现出更高的阳性反馈反应发生率(12只中的8只,即66.7%)。在其中3例中观察到伴随的促卵泡生成素(FSH)激增。然而,当在纳美芬治疗组中雌激素激发试验前下降的孕酮浓度用外源性孕酮补充时,纳美芬未能引发任何LH激增。通过皮下输注接受纳美芬的8只动物中有6只表现出LH反应。然而,这些LH反应的幅度和持续时间减小,并且未观察到FSH反应。在激发试验前用纳美芬预处理较短(24小时)或较长(96小时)时间的猴子反应性较低(分别为6次试验中0次反应和4次试验中1次反应)。纳美芬在预防卵泡期动物中孕酮对雌二醇诱导的LH激增的抑制方面同样无效(15只动物中0只出现LH激增)。这些结果表明,当孕酮水平较高时,如在黄体期或给予孕酮后,内源性阿片类物质的纳美芬拮抗作用并不能使雌激素对LH释放发挥阳性反馈作用。(摘要截短至400字)